Exchange: NYSEArca·Updated 05:23 AM EDT
News
all
press releases
MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
MoonLake has consistently guided for a “mid-2026” primary endpoint readout from IZAR-1, its late-stage trial for sonelokimab in certain patients with active psoriatic arthritis.
Stocktwits
More News
VHT vs. PBE: Which Health Care ETF Is the Better Buy?
Key PointsThe Vanguard Health Care ETF (VHT) offers broader health care exposure and has a a lower expense ratio than the Invesco Biotechnology & Genome ETF (PBE...
Nasdaq News: Markets
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees
Key PointsVanguard Health Care ETF offers a lower expense ratio and a higher dividend yield than VanEck Biotech ETF...
Nasdaq News: Markets
UnitedHealth Pulls Back Post 52-Week High: Healthcare ETFs to Watch
UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.
Zacks
ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook
Johnson & Johnson's Q2 beat and strong pharma momentum are raising interest in healthcare ETFs with sizable exposure to the company.
Zacks
Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?
Key PointsVanguard Health Care ETF offers a significantly lower expense ratio of 0.09% compared to 0.38% for iShares U.S. Pharmaceuticals ETF...
Nasdaq News: Markets
As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026?
Key PointsVanguard Health Care ETF offers a lower expense ratio and higher dividend yield than Invesco Pharmaceuticals ETF...
Nasdaq News: Markets
Are the Odds of a Wider Middle East Conflict Rising? ETFs to Consider
Nine consecutive days of U.S. airstrikes and ongoing retaliatory attacks have heightened fears of a broader Middle East conflict. Here are some ETFs that could benefit.
Zacks
3 Vanguard ETFs Poised to Outperform as the Market Shifts Beyond Big Tech
Key PointsThe Vanguard Health Care ETF is already in rally mode...
Nasdaq News: Markets
Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge
JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.
Zacks

Advertisement|Remove ads.